<DOC>
	<DOCNO>NCT00495547</DOCNO>
	<brief_summary>The primary objective evaluate efficacy treatment response rate term . Otherwise study want evaluate safety treatment .</brief_summary>
	<brief_title>SIMIDIS : Azacitidine Beta Erythropoietin Treatment Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description>A total 30 patient diagnosed myelodysplastic syndrome red cell transfusion dependent low intermediate -1 risk include . The patient evaluate scheduled visit three study period : Pre-treatment , Treatment Follow . The Pre-treatment include Screening baseline visit . After provide informed consent , patient evaluate study eligibility . During Treatment Period patient evaluate month although biochemistry haematology parameter evaluate every 2 week . If erythroid response 24 week determine , extension treatment carry without disease progression .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . Must voluntary sign inform consent . 2 . Age ≥ 18 year . 3 . Must able comply protocol requirement 4 . Patient recently diagnose Myelodysplastic syndrome red cell transfusion dependent low intermediate 1 risk accord IPSS criterion . 5 . Red cell transfusion dependent anemia . 6 . El patient able complain protocol visit . 7 . Women man must accept use high efficacy anticonceptive method 1 . Pregnancy breastfeed woman . 2 . Patients previously receive treatment azacytidine . 3 . Patients previously receive treatment erythropoietin agent . 4 . Proliferative Chronic myelomonocytic Leukaemia ( leukocytes ≥ 12000/mL ) . 5 . Patient previous clinical history another cancer ( except basocellular carcinoma spinocellular carcinoma situ cervix breast ) except patient free symptom ≥ 3 year . 6 . Cytotoxic chemotherapy experimental agent usage myelodysplastic syndrome treatment 28 day . 7 . Previous haematopoietic transplant . 8 . Mielosupresion antitumoral treatment previous 28 day . 9 . The following laboratory data : Absolute neutrophil count &lt; 1000 cel/ml ( 0.5x 109L ) Platelet count &lt; 50000/μL ( 25 x 109/L ) Creatinine &gt; 2.0 mg/dL ( 177 mmol/L ) Aspartate transaminase ( AST ) Alanine transaminase ( ALT ) &gt; 5 x upper limit normal . Total bilirubin : &gt; 2 mg/dL 10 . Patients B12 vitamin , folic acid ferrum deficiency . 11 . Patient positive VIH1 . 12 . Any organic mental illness could make impossible sign Inform consent involve risk patient . 13 . Patient hypersensitivity previous beta , azacytidine , erythropoietin and/or mannitol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Red Cell transfusion dependent</keyword>
</DOC>